Arcellx's Acquisition by Gilead Sciences and Its Impact on Stock Performance

Cory Kasimov from Evercore ISI set a price target of $115 for NASDAQ:ACLX, indicating a slight 1.04% difference from its current trading price.Gilead Sciences plans to acquire Arcellx for up to $7.8 billion, aiming to enhance its cancer treatment portfolio.The acquisition news has led to a significant increase in ACLX's stock price, soaring 77.8% in premarket trading and reflecting a 77.50% rise to $113.80.Arcellx, listed on the NASDAQ:ACLX, is a biotechnology company focused on developing innovative cancer ...